Spinal cord stimulation (also known as “SCS”) therapy has been used to combat chronic pain since 1967. The FDA approved spinal cord stimulation in 1989 for the relief of intractable pain in the torso, arms, and legs.
SCS works by sending mild electrical pulses to nerves along the spinal column. The pulses interrupt pain signals before they reach the brain. SCS therapy essentially tricks the brain into feeling only numbness or a mild tingling sensation, instead of the constant searing agony of incurable chronic pain.
Currently, the primary use of SCS is to help avoid a back surgery that may prove to be futile. The second most common application of SCS is to alleviate the intolerable pain associated with complex regional pain syndrome (CRPS). SCS is also used to relieve peripheral neuropathic pain related to nerve damage from viral infection, surgery, or diabetes.
But spinal cord stimulation is not a panacea for patients suffering from CRPS or failed back surgery syndrome. For example, more than half of CRPS patients fail to achieve any meaningful pain relief with SCS.
In February 2016, the FDA approved a new pain relief technique called dorsal root ganglion (DRG) stimulation. While DRG stimulation is similar to spinal cord stimulation, it varies in significant respects.
The ACCURATE study was conducted at 22 investigational sites spread across the United States. The study recruited 152 subjects, each of whom had been diagnosed with chronic complex regional pain syndrome in their legs. The participants were randomly placed into two groups. One group received DRG stimulation therapy and the other received standard spinal cord stimulation.
The results of the ACCURATE research are quite impressive. Participants receiving DRG stimulation had a higher rate of treatment success (81.2%). The success rate for traditional SCS was (56.7%). The pain relief from DRG stimulation continued through 12 months of follow-up.
The results of a new study of DRG stimulation and chronic back pain were recently reported at the annual meeting of the American Society of Anesthesiologists in San Francisco. The project was led by Robert McCarthy, PharmD., who is a professor of anesthesiology at Rush University Medical Center in Chicago. McCarthy and his colleagues focused on 67 people who suffered from chronic back pain. The study’s participants were each implanted with a dorsal root ganglion stimulator.
“People in our study who had DRG stimulation reported significant improvement in pain even after a year, which is notable,” said McCarthy. “They had tried numerous therapies, from drugs to spinal cord stimulation to surgery, but got little or no lasting pain relief. For most, DRG stimulation improved their quality of life.”
Before the DRG devices were implanted, many of the participants rated their back pain as an 8 on a scale of 1 to 10. They were followed for 3 to 18 months after the devices were implanted. For most, DRG stimulation reduced their pain by one third. The participants also reported that the limitations on their daily activities were reduced by 27% and 94% said the treatment was beneficial.
Although DRG stimulation therapy was approved by the FDA in 2016, it is still not widely available. According to McCarthy, DRG stimulation therapy is offered only in advanced medical research centers, where doctors are trained in implantation and regulation techniques. Dr. Vadhedifar is highly proficient in these techniques and we offer DRG stimulation therapy at Nuvo Spine.
DRG stimulation is covered by Medicare, and Blue Cross/Blue Shield cover it when it’s deemed to be medically necessary, but not all insurance companies will pay for the procedure. For uninsured patients, the cost can be daunting ($15,000 – $50,000).
We approach our work armed with tried and true medical techniques and state-of-the-art regenerative strategies bred from sports medicine and the neurological sciences.
The Nuvo team of medical professionals is solely dedicated to minimizing or eradicating pain by resolving the underlying conditions that cause the pain. We are proud that we consistently achieve that goal and successfully enhance our patients’ overall quality of life.
To request more information or schedule a consultation, please call (888) 370-9334 or make your appointment online.
Read the full article at: www.chicagotribune.com
You Might Also Enjoy...
Australian research scientists have devised a new blood test to measure pain called “painHS”. They say the “painHS” will soon be an accurate tool for objectively telling doctors how much pain their patient is suffering from.
Kelly Thomas and Jeff Marquis learn to walk again thanks to a spinal cord implant. They participated in a study from the Kentucky Spinal Cord Injury Research Center at the University of Louisville.
Neuropathic pain is nasty. It is baffling and excruciating. It’s also defined as chronic pathological pain that continues after the physiological cause has been eliminated. It can cause even the lightest of feathery touches to produce intolerable pain.
Data from 6 studies show that virtual reality (VR) is beneficial in the treatment of pain in adults and children. The immersive nature of VR may explain why the technique is effective.
Resiniferatoxin is 10,000 times hotter than the hottest pepper, and has features that make it promising as a painkiller of last resort.
This story is really about why females (both laboratory animals and humans) must be properly represented in medical research designed to alleviate pain. But the National Institutes of Health (NIH) primer which generated this article deals specifically with
